| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università "Federico II"; 2 Cattedra di Oncologia Medica, Seconda Universita degli Studi di Napoli, Napoli, Italy; 3 The Breast Center at Baylor College of Medicine and The Methodist Hospital; 4 Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas; and 5 Divisione di Oncologia Medica, Ospedale "G. Rummo," Benevento, Italy
Requests for reprints: Michele De Laurentiis, Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università "Federico II," via Sergio Pansini, 5, 80131 Napoli, Italy. Phone: 39-81-7464286; Fax: 39-81-2290150; E-mail: michele.delaurentiis{at}unina.it.
Purpose: Experimental data suggest a complex cross-talk between HER-2 and estrogen receptor, and it has been hypothesized that HER-2-positive tumors may be less responsive to certain endocrine treatments. Clinical data, however, have been conflicting. We have conducted a meta-analysis on the interaction between the response to endocrine treatment and the overexpression of HER-2 in metastatic breast cancer.
Experimental Design: Studies have been identified by searching the Medline, Embase, and American Society of Clinical Oncology abstract databases. Selection criteria were (a) metastatic breast cancer, (b) endocrine therapy (any line of treatment), and (c) evaluation of HER-2 expression (any method). For each study, the relative risk for treatment failure for HER-2-positive over HER-2-negative patients with 95% confidence interval was calculated as an estimate of the predictive effect of HER-2. Pooled estimates of the relative risk were computed by the Mantel-Haenszel method.
Results: Twelve studies (n = 2,379 patients) were included in the meta-analysis. The overall relative risk was 1.42 (95% confidence interval, 1.32-1.52; P < 0.00001; test for heterogeneity = 0.380). For studies involving tamoxifen, the pooled relative risk was 1.33 (95% confidence interval, 1.20-1.48; P < 0.00001; test for heterogeneity = 0.97); for studies involving other hormonal drugs, a pooled relative risk of 1.49 (95% confidence interval, 1.36-1.64; P < 0.00001; test for heterogeneity = 0.08) was estimated. A second meta-analysis limited to tumors that were either estrogen receptor positive, estrogen receptor unknown, or estrogen receptor negative/progesterone receptor positive yielded comparable results.
Conclusions: HER-2-positive metastatic breast cancer is less responsive to any type of endocrine treatment. This effect holds in the subgroup of patients with positive or unknown steroid receptors.
This article has been cited by other articles:
|
|
 |
|
  C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann. Onc., July 1, 2009; 20(7): 1157 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Barone, Y. Cui, M. H. Herynk, A. Corona-Rodriguez, C. Giordano, J. Selever, A. Beyer, S. Ando, and S. A.W. Fuqua Expression of the K303R Estrogen Receptor-{alpha} Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway Cancer Res., June 1, 2009; 69(11): 4724 - 4732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. P. O'Malley, S. Chia, D. Tu, L. E. Shepherd, M. N. Levine, V. H. Bramwell, I. L. Andrulis, and K. I. Pritchard Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy J Natl Cancer Inst, May 6, 2009; 101(9): 644 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Merglen, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, V. Vinh-Hung, G. Vlastos, P. O. Chappuis, M. Castiglione, E. Rapiti, and C. Bouchardy Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality Ann. Onc., May 1, 2009; 20(5): 857 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations Am J Clin Pathol, April 1, 2009; 131(4): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Pritchard, M. Trudeau, H. Messersmith, L. Elavathil, F. O'Malley, and B. Dhesy-Thind In Reply J. Clin. Oncol., May 20, 2008; 26(15): 2596 - 2597. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance Endocr. Rev., April 1, 2008; 29(2): 217 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Pritchard, H. Messersmith, L. Elavathil, M. Trudeau, F. O'Malley, and B. Dhesy-Thind HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy J. Clin. Oncol., February 10, 2008; 26(5): 736 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Massarweh, C. K. Osborne, C. J. Creighton, L. Qin, A. Tsimelzon, S. Huang, H. Weiss, M. Rimawi, and R. Schiff Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function Cancer Res., February 1, 2008; 68(3): 826 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dowsett Factors Predicting Response and Resistance to Endocrine Therapy of Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 14 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Veneziani, V. Criniti, C. Cavaliere, S. Corvigno, A. Nardone, S. Picarelli, G. Tortora, F. Ciardiello, G. Limite, and S. De Placido In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches Mol. Cancer Ther., December 1, 2007; 6(12): 3091 - 3100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.S. Bartlett, I. O. Ellis, M. Dowsett, E. A. Mallon, D. A. Cameron, S. Johnston, E. Hall, R. A'Hern, C. Peckitt, J. M. Bliss, et al. Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4423 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pietras and D. C. Marquez-Garban Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers Clin. Cancer Res., August 15, 2007; 13(16): 4672 - 4676. [Full Text] [PDF]
|
|
|
|
|
|
S Dawood and M Cristofanilli Endocrine resistance in breast cancer: what really matters? Ann. Onc., August 1, 2007; 18(8): 1289 - 1291. [Full Text] [PDF]
|
|
|
|
|
|
G. Arpino, C. Gutierrez, H. Weiss, M. Rimawi, S. Massarweh, L. Bharwani, S. De Placido, C. K. Osborne, and R. Schiff Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy J Natl Cancer Inst, May 2, 2007; 99(9): 694 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P.V. Shekhar, S. Santner, K. A. Carolin, and L. Tait Direct Involvement of Breast Tumor Fibroblasts in the Modulation of Tamoxifen Sensitivity Am. J. Pathol., May 1, 2007; 170(5): 1546 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Massarweh and R. Schiff Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities Clin. Cancer Res., April 1, 2007; 13(7): 1950 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Massarweh and R. Schiff Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S15 - S24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vocaturo, F. Novelli, M. Benevolo, G. Piperno, F. Marandino, A. M. Cianciulli, R. Merola, R. P. Donnorso, I. Sperduti, S. Buglioni, et al. Chromogenic In Situ Hybridization to Detect HER-2/neu Gene Amplification in Histological and ThinPrep(R)-Processed Breast Cancer Fine-Needle Aspirates: A Sensitive and Practical Method in the Trastuzumab Era Oncologist, September 1, 2006; 11(8): 878 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Glaros, N. Atanaskova, C. Zhao, D. F. Skafar, and K. B. Reddy Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen Mol. Endocrinol., May 1, 2006; 20(5): 996 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ellis Functional Analysis of the Breast Cancer Genome J. Clin. Oncol., April 10, 2006; 24(11): 1649 - 1650. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
